Online inquiry

IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ14994MR)

This product GTTS-WQ14994MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.

Specifications
Product type	mRNA
Modified bases	N1-Methylpseudo-UTP
5' Cap	Cap 1
Species	Chimeric
RefSeq	NM_001178098.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	930
UniProt ID	P15391

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14994MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ15846MR	IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	XmAb-18087
GTTS-WQ9589MR	IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	JNJ-61610588
GTTS-WQ12744MR	IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	OMP-313M32
GTTS-WQ9385MR	IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	Interleukin 2
GTTS-WQ9270MR	IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	IMMU-130
GTTS-WQ4572MR	IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	BMS-986004
GTTS-WQ7677MR	IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, Pseudo-UTP, 30 nt-poly(A))	mRNA	GEN3013
GTTS-WQ11731MR	IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	MK-0646

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST